title: Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
abstract: Although Hodgkin's lymphoma is considered a highly curable cancer, a substantial portion of patients will be refractory or will relapse after first-line therapies and even after subsequent autologous stem cell transplantation. With the absence of effective salvage therapies, these patients carry a poor prognosis with dismal survival. In this therapeutic void, the antibody-drug conjugate brentuximab vedotin was introduced and has since yielded impressive and durable response with minimal and reversible toxicity. Such efficacy in the relapse-refractory setting has led to new hypotheses and dramatic changes in our treatment strategies of Hodgkin's lymphoma. Numerous clinical trials evaluating brentuximab in the frontline and various other treatment settings are forthcoming and will demonstrate the full extent of the drug's impact.
authors.affiliation: Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010, USA.
authors.forename: Anh
authors.initials: A
authors.lastname: Pham
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
keywords: CD30; Hodgkin’s lymphoma; Reed–Sternberg; allogeneic stem cell transplantation; antibody–drug conjugate; autologous stem cell transplantation; brentuximab vedotin; refractory disease; relapsed disease